Barigen.com’s medical information should be maintained using current regulatory and scientific sources.
U.S. prescribing information
Daily Med — OLUMIANT (baricitinib)
The current label includes indications, dosing, warnings, adverse reactions, interactions, pharmacology and clinical-study information.
FDA
FDA regulatory materials should be used when evaluating U.S. approvals and label changes.
European Medicines Agency
EMA — Olumiant EPAR
The EMA provides current European product information and authorized indications for baricitinib.
The current EMA product information was updated in May 2026.
Clinical literature
Relevant evidence includes studies evaluating baricitinib in:
- Rheumatoid arthritis
- Alopecia areata
- Atopic dermatitis
- Juvenile idiopathic arthritis
- COVID-19
Clinical evidence should be interpreted in the context of the specific population and indication studied.
Product information
Public product sources identify Barigen 4 mg as a baricitinib product associated with General Pharmaceuticals Ltd.